Antimicrobial Agents and Chemotherapy · 2020 · 14 citations · 14 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceInnate ImmunityMedical MicrobiologyAcquired ResistanceAntibacterial ResistanceAntibiotic ResistanceBacterial InfectionsOpportunistic Infection ManagementOpportunistic InfectionsAntibacterial ImmunityDrug Resistance In Opportunistic PathogensHost Iron-withholding ResponsesIntranasal AdministrationIntranasal RetentionMethicillin-resistant Staphylococcus Aureus Infection TreatmentMethicillin-resistant Staphylococcus Aureus TreatmentResistance In Clinical Isolates
(MRSA) opportunistic infections are a major health burden. Decolonization of hospitalized patients with mupirocin (MUP) has reduced the incidence of infection but has led to MUP resistance. DIBI is a developmental-stage anti-infective agent that sequesters bacterial iron and bolsters innate host iron-withdrawal defenses. Clinical isolates possessing low, high, or no MUP resistance all had similarly high susceptibilities to DIBI. Intranasal DIBI reduced nares bacterial burdens in mice to the same extent as MUP. No resistance was found after exposure to DIBI.
14